Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02228811 · ClinicalTrials.gov registry record · Phase 1
A Study of DCC-2701 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Deciphera Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT02228811 is a Phase 1 study that was terminated before completion, run by Deciphera Pharmaceuticals. The registered enrollment target is 44 participants.
The verdict
NCT02228811, a Phase 1 study, was terminated before completion, sponsored by Deciphera Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The main purpose of this study is to investigate the safety of the investigational drug DCC-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to other parts of the body.
Interventions
- DRUG DCC-2701 tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2014-06 |
| Est. Completion | 2018-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02228811
The ClinicalTrials.gov registry entry for NCT02228811 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deciphera Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DCC-2701 tablet is the first listed.
NCT02228811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02228811 about?
NCT02228811 is a clinical study titled "A Study of DCC-2701 in Participants With Advanced Solid Tumors". The main purpose of this study is to investigate the safety of the investigational drug DCC-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to other parts of the body.
What is the current status of trial NCT02228811?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2014-06. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02228811?
The interventions under investigation include: DCC-2701 tablet (DRUG).
Who is sponsoring clinical trial NCT02228811?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.